Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 16.09.2024 1 Cancer 1 Cancer Res 1 Endocrinology 4 Eur Urol 2 Int J Urol 3 J Urol 1 N Engl J Med 1 Nat Rev Urol 1 Oncogene 1 Oncology 1 PLoS One 2 Prostate 1 Radiol Artif Intell 1 Radiology 4 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Cancer

1. KILBRIDGE KL, Patil D, Filson CP, Shelton JW, et al
   Tailoring language for genitourinary function in patients with newly diagnosed prostate cancer to facilitate discussions in diverse populations and overcome health literacy barriers.
   Cancer. 2024 Sep 10. doi: 10.1002/cncr.35498.
   PubMed         Abstract available
   
   

   
   Cancer Res

2. RODARTE KE, Nir Heyman S, Guo L, Flores L, et al
   Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.
   Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-1388.
   PubMed         Abstract available
   
   

   
   Endocrinology

3. ANDOLFI C, Bartolini C, Morales E, Gundogdu B, et al
   MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer.
   Endocrinology. 2024;165:bqae114.
   PubMed         Abstract available
   
   

   
   Eur Urol

4. VAN AS N, Yasar B, Griffin C, Patel J, et al
   Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
   Eur Urol. 2024 Sep 11:S0302-2838(24)02568-5. doi: 10.1016/j.eururo.2024.
   PubMed         Abstract available
   
   
5. LI R, Peng L, Zhang S, Wu S, et al
   Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.
   Eur Urol. 2024 Sep 5:S0302-2838(24)02564-8. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   
6. ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
   Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
   Eur Urol. 2024 Sep 5:S0302-2838(24)02560-0. doi: 10.1016/j.eururo.2024.
   PubMed         Abstract available
   
   
7. ACHARD V, Tombal B
   All Biochemical Recurrences Are Equal, but Some Are More Equal than Others.
   Eur Urol. 2024;86:211-212.
   PubMed        
   
   

   
   Int J Urol

8. SHIMADA K, Fujiwara M, Hirahara D, Takaya E, et al
   Monitoring prostate cancer after low-dose-rate hemigland brachytherapy with delta-radiomics of diffusion-weighted magnetic resonance imaging.
   Int J Urol. 2024 Sep 11. doi: 10.1111/iju.15581.
   PubMed        
   
   
9. KAMBE T, Yamasaki T, Yamamoto A, Nagoshi A, et al
   Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
   Int J Urol. 2024 Sep 10. doi: 10.1111/iju.15579.
   PubMed         Abstract available
   
   

   
   J Urol

10. CHOUDRY MM, Durant AM, Edmonds VS, Warren CJ, et al
    Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.
    J Urol. 2024;212:590-599.
    PubMed         Abstract available
    
    
11. MA C
    Letter: Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:627-628.
    PubMed        
    
    
12. YAXLEY JW
    Letter: Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:628.
    PubMed        
    
    

    
    N Engl J Med

13. GANGULI I
    How Does Health Care Burden Patients? Let Me Count the Days.
    N Engl J Med. 2024;391:880-883.
    PubMed        
    
    

    
    Nat Rev Urol

14. LAWLOR A, Beyer K, Russell B, Steinbeisser C, et al
    PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.
    Nat Rev Urol. 2024 Sep 9. doi: 10.1038/s41585-024-00925.
    PubMed         Abstract available
    
    

    
    Oncogene

15. SARDAR S, McNair CM, Ravindranath L, Chand SN, et al
    AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Oncogene. 2024 Sep 13. doi: 10.1038/s41388-024-03148.
    PubMed         Abstract available
    
    

    
    Oncology

16. MASUDA R, Noguchi Y, Aizawa H, Yoshizawa S, et al
    Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan.
    Oncology. 2024 Aug 14:1-9. doi: 10.1159/000540864.
    PubMed         Abstract available
    
    

    
    PLoS One

17. WENNERBERG C, Ekstedt M, Schildmeijer K, Hellstrom A, et al
    Effects on patient activation of eHealth support in addition to standard care in patients after radical prostatectomy: Analysis of secondary outcome from a randomized controlled trial.
    PLoS One. 2024;19:e0308555.
    PubMed         Abstract available
    
    

    
    Prostate

18. LIU X, Zhu J, Shi MQ, Pan YS, et al
    Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography.
    Prostate. 2024 Sep 12. doi: 10.1002/pros.24789.
    PubMed         Abstract available
    
    
19. BOIARSKY D, Tewari AK, Gulhan DC, Bakouny Z, et al
    A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
    Prostate. 2024 Sep 9. doi: 10.1002/pros.24788.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

20. LI H, Liu H, von Busch H, Grimm R, et al
    Deep Learning-based Unsupervised Domain Adaptation via a Unified Model for Prostate Lesion Detection Using Multisite Biparametric MRI Datasets.
    Radiol Artif Intell. 2024 Aug 21:e230521. doi: 10.1148/ryai.230521.
    PubMed         Abstract available
    
    

    
    Radiology

21. TAKAHASHI T
    Rationale for MRI-guided Focused Ultrasound Focal Therapy for Prostate Cancer.
    Radiology. 2024;312:e240738.
    PubMed        
    
    

    
    Urology

22. BULUSU A, Ferrante S, Wu RC, Qi J, et al
    Reply to Editorial Comment on "Current Perceptions, Practice Patterns, and Barriers to Adoption of Transperineal Prostate Biopsy Under Local Anesthesia".
    Urology. 2024;191:20-21.
    PubMed        
    
    
23. DALL CP, Liu X, Faraj KS, Srivastava A, et al
    Teaching Hospitals and Textbook Outcomes After Major Urologic Cancer Surgery.
    Urology. 2024;191:64-70.
    PubMed         Abstract available
    
    
24. LIU AQ, Chiu PK
    Editorial Comment on Article "Current Perceptions, Practice Patterns, and Barriers to Adoption of Transperineal Prostate Biopsy Under Local Anesthesia".
    Urology. 2024;191:19-20.
    PubMed        
    
    
25. BULUSU A, Ferrante S, Wu RC, Qi J, et al
    Current Perceptions, Practice Patterns, and Barriers to Adoption of Transperineal Prostate Biopsy Under Local Anesthesia.
    Urology. 2024;191:12-18.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.